![Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis](https://mma.prnewswire.com/media/952447/Boehringer_Ingelheim_Logo.jpg?p=twitter)
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
![Boehringer Ingelheim, Evotec and BioMérieux Launch Aurobac, a joint venture to fight Antimicrobial Resistance – News & Updates Boehringer Ingelheim, Evotec and BioMérieux Launch Aurobac, a joint venture to fight Antimicrobial Resistance – News & Updates](https://chemrobotics.in/wp-content/uploads/2022/07/download--300x162.jpg)
Boehringer Ingelheim, Evotec and BioMérieux Launch Aurobac, a joint venture to fight Antimicrobial Resistance – News & Updates
![Deaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma, Hanmi Stock Tanks | BioSpace Deaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma, Hanmi Stock Tanks | BioSpace](http://enewsletters.biospace.com/images/news/biospace-news-815x450-boehringer-ingelheim.jpg)
Deaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma, Hanmi Stock Tanks | BioSpace
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
![Manufacturing News of Note—Samsung Bioepis, Biogen add to biosimilars; Boehringer Ingelheim to add 105 jobs in Puerto Rico | Fierce Pharma Manufacturing News of Note—Samsung Bioepis, Biogen add to biosimilars; Boehringer Ingelheim to add 105 jobs in Puerto Rico | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1573745216/business-1730089_1920.jpg/business-1730089_1920.jpg?VersionId=FrycRi29AisXblIg_GN96GfTM2C5fHab)
Manufacturing News of Note—Samsung Bioepis, Biogen add to biosimilars; Boehringer Ingelheim to add 105 jobs in Puerto Rico | Fierce Pharma
![Boehringer Ingelheim Acquiring NBE Therapeutics For $1.5 Billion | by Bare Sky Marketing — Healthcare Content Writing | Medium Boehringer Ingelheim Acquiring NBE Therapeutics For $1.5 Billion | by Bare Sky Marketing — Healthcare Content Writing | Medium](https://miro.medium.com/max/700/1*BLjyy2adirqP9dFU66UNHQ.jpeg)
Boehringer Ingelheim Acquiring NBE Therapeutics For $1.5 Billion | by Bare Sky Marketing — Healthcare Content Writing | Medium
![jardiance: Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failure - The Economic Times jardiance: Boehringer Ingelheim's diabetes pill Jardiance gets CDSCO nod for use against heart failure - The Economic Times](https://img.etimg.com/thumb/msid-87848123,width-300,height-225,imgsize-23866,,resizemode-75/4-pharma-names-among-top-10-stocks-that-retail-investors-are-selling-now.jpg)